報價延遲最少15分鐘:2025/01/21 18:52 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
6.19 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.47/-1.16
|
|
企業價值
283.39M
|
| 資產負債 |
|
每股賬面淨值
2.38
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
68.68M
|
|
每股收益
1.64
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/21 18:52 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions. |